Overview

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Status:
Recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Collaborators:

Biontech RNA Pharmaceuticals GmbH
BioNTech SE

Treatments:

Antibodies, Monoclonal
Atezolizumab